- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07479043
Att utvärdera säkerheten och den potentiella terapeutiska aktiviteten av JadiCell™, en experimentell mesenkymal stamcellsterapi härrörande från navelsträng, hos patienter med diagnosen akut respiratorisk distress-syndrom (ARDS).
Fas III klinisk studie av JadiCell™ (mesenkymala stamceller från navelsträngen) för behandling av akut andningsdistressyndrom (ARDS)
This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS). JadiCells are administered intravenously and are intended to modulate inflammatory responses and promote tissue repair in injured lung tissue.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by severe inflammatory lung injury, impaired oxygen exchange, and high mortality. Current treatments are primarily supportive and include mechanical ventilation and intensive care management.
JadiCell™ is an investigational cellular therapy derived from human umbilical cord tissue. These cells possess immunomodulatory and regenerative properties and may reduce inflammatory lung injury through paracrine signaling, immune regulation, and tissue repair mechanisms.
Following intravenous administration, mesenchymal stem cells are known to localize within the pulmonary microvasculature where they interact with immune cells and injured lung tissue.
This study will evaluate the safety and potential clinical effects of intravenous JadiCell administration in patients with ARDS.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients currently hospitalized
- Laboratory confirmation of ARDS
- Aged between 18 and 80 years
- Willing and able to provide written informed consent, or with a legal representative who can provide informed consent
- SpO2 <94% on room air requiring supplemental oxygen above baseline
- PaO2/FiO2 <300 mmHg
- Bilateral infiltrates on frontal chest radiograph or bilateral ground glass opacities on a chest CT scan
- Requiring one of the following ï High Flow Oxygen Therapy ï Non-invasive Positive Pressure Ventilation (NIPPV, e.g. BiPAP and CPAP) ï Invasive Mechanical Ventilation (INV = intubated)
Exclusion Criteria:
- Greater than 96 h since hospitalization at the time of enrollment
- Greater than 48 h since intubation at the time of enrollment
- A previous MSC infusion not related to this trial
- History of Pulmonary Hypertension (WHO Class III/IV)
- History of left atrial hypertension or decompensated left heart failure.
- Pregnant or lactating patient
- Unstable arrhythmia
- Patients currently receiving immunosuppression with exception of up to 10 mg Prednisone equivalents daily
- Patients currently receiving chronic dialysis
- Patients currently receiving Extracorporeal Membrane Oxygenation (ECMO)
- Presence of any active malignancy (except non-melanoma skin cancer)
- Moderate to severe liver disease (AST and ALT >5 X ULN)
- Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen at rest
- Septic Shock (with >1 vasopressor)
- Multi-organ failure
- Not expected to survive > 48 hours
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Faktoriell uppgift
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment
Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100±20 x106 UC-MSC. |
Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100±20 x106 UC-MSC. |
|
Placebo-jämförare: Control
Controls will receive two infusions of vehicle solution. |
Subjects in the control group will be treated with two IV infusions of vehicle solution. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of Participants Alive and Free of Respiratory Failure
Tidsram: 60 days
|
The proportion of participants who are alive and free of respiratory failure following treatment with UC-MSC therapy. |
60 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
1. All-Cause Mortality
Tidsram: 60 Days
|
Number of Participants Who Died (All-Cause Mortality) |
60 Days
|
|
2. Survival Status
Tidsram: 31 Days
|
Number of Participants Alive at Day 31 |
31 Days
|
|
3. Incidence of Serious Adverse Events (SAEs)
Tidsram: 31 Days
|
Number of Participants Experiencing Serious Adverse Events (SAEs) |
31 Days
|
|
4. Serious Adverse Event-Free Survival
Tidsram: 31 Days
|
Number of Participants Alive Without Serious Adverse Events |
31 Days
|
|
5. Time to Clinical Recovery
Tidsram: Up to 60 Days
|
Time to Clinical Recovery (Days) |
Up to 60 Days
|
|
6. Time to Oxygen Requirement ≤ 40%
Tidsram: Up to 60 Days
|
Time to Oxygen Requirement ≤ 40% (Days) |
Up to 60 Days
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- BRTH001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .